The BCR-ABL Gene Rearrangement Quantitative by RT-PCR test is a molecular diagnostic test used to detect and measure the BCR-ABL fusion gene, which results from a chromosomal translocation known as the Philadelphia chromosome. This abnormal gene is commonly associated with chronic myeloid leukemia (CML) and some cases of acute lymphoblastic leukemia (ALL). The test is performed to confirm diagnosis, monitor disease progression, and assess treatment response, especially in patients receiving targeted therapies like tyrosine kinase inhibitors.
It confirms diagnosis, monitors disease progression, and evaluates treatment response, especially for patients receiving tyrosine kinase inhibitors.
A positive result confirms the presence of the BCR-ABL fusion gene, supporting diagnosis and treatment planning.
It suggests no detectable BCR-ABL fusion gene, ruling out CML or BCR-ABL–positive ALL.
No, medications do not interfere with genetic transcript detection.
Yes, it is safe and can be performed in pediatric patients when clinically indicated.
Without testing, diagnosis may be delayed, and treatment effectiveness cannot be properly monitored.
No, they are genetic changes, but early detection helps guide therapy.
Positive results are associated with chronic myeloid leukemia and some acute lymphoblastic leukemia cases.
...
Didn't recieved OTP Yet? Resend OTP